MARKET

PRME

PRME

Prime Medicine
NASDAQ
1.300
-0.020
-1.52%
After Hours: 1.300 0 0.00% 17:08 05/09 EDT
OPEN
1.330
PREV CLOSE
1.320
HIGH
1.490
LOW
1.270
VOLUME
1.39M
TURNOVER
--
52 WEEK HIGH
8.27
52 WEEK LOW
1.115
MARKET CAP
170.51M
P/E (TTM)
-0.7871
1D
5D
1M
3M
1Y
5Y
1D
Prime Medicine, Inc.: Buy Rating Backed by Promising Gene Editing Advancements and Robust Pipeline
TipRanks · 17h ago
Prime Medicine Reports Q1 2025 Financial Results
TipRanks · 22h ago
Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Prime Medicine, Inc. (PRME)
TipRanks · 1d ago
Prime Medicine sees cash runway into 1H26
TipRanks · 1d ago
Prime Medicine Q1 EPS $(0.40) Misses $(0.36) Estimate, Sales $1.45M Beat $1.05M Estimate
Benzinga · 1d ago
*Prime Medicine Cash, Cash Equivalents, Investments, and Restricted Cash Were $158.3M at March 31 >PRME
Dow Jones · 1d ago
*Prime Medicine 1Q Rev $1.45M >PRME
Dow Jones · 1d ago
*Prime Medicine 1Q Loss $51.9M >PRME
Dow Jones · 1d ago
More
About PRME
More
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
Recently
Symbol
Price
%Change

Webull offers Prime Medicine Inc stock information, including NASDAQ: PRME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRME stock methods without spending real money on the virtual paper trading platform.